Harmony Biosciences Holdings, INC 8-K filings

Harmony Biosciences announced record Q2 2026 revenue of $261.3 million, a 30% year-over-year increase, and presented encouraging clinical data for its orexin-2 agonist BP-205.

Harmony Biosciences announced preliminary record net product revenue of approximately $261 million for Q2 2026, a 30% year-over-year increase, and reaffirmed its full-year revenue guidance.

Harmony Biosciences announced Q1 2026 financial results, with WAKIX net revenue growing 17% year-over-year to $215.4 million, and reaffirmed its full-year 2026 net revenue guidance of over $1 billion.

Harmony Biosciences Holdings, Inc. announced the appointment of Glenn Reicin as its new Chief Financial Officer, effective April 14, 2026, and reiterated its 2026 net revenue guidance of over $1 billion for Wakix sales.

Harmony Biosciences has appointed Peter Anastasiou as Chief Operating Officer and announced strategic changes to its Board of Directors.

Harmony Biosciences announced robust 2025 financial results, with WAKIX net revenue reaching $868.5 million, and reiterated its 2026 guidance of over $1 billion, driven by pipeline advancements and market expansion.

Harmony Biosciences announced strong preliminary 2025 WAKIX revenue and provided 2026 guidance, alongside updates on its robust late-stage pipeline.

Harmony Biosciences announced robust Q3 2025 financial results driven by WAKIX growth, raising full-year revenue guidance, while facing a setback in its ZYN002 Fragile X syndrome trial.

Harmony Biosciences announced strong preliminary Q3 2025 WAKIX performance, with $239 million in net product revenue and an increased full-year 2025 revenue guidance to $845-$865 million.

Harmony Biosciences announced its Phase 3 RECONNECT study for ZYN002 in Fragile X syndrome did not meet its primary endpoint due to a high placebo response.

Harmony Biosciences reported robust Q2 2025 financial results, driven by WAKIX growth, and reaffirmed its full-year revenue guidance while advancing a promising late-stage pipeline.

Harmony Biosciences announced strong preclinical results for its investigational OX2R agonist, BP1.15205, showing significant wake-promoting and cataplexy-suppressing effects, with a first-in-human study planned for late 2025.

Harmony Biosciences Holdings, Inc. announced a settlement agreement with Lupin Limited, resolving patent infringement litigation and securing WAKIX's market exclusivity until at least January 2030.

Harmony Biosciences Holdings held its 2025 Annual Meeting of Stockholders on May 15, 2025, where stockholders elected three Class II directors and ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Harmony Biosciences announces a 20% year-over-year revenue increase for Q1 2025, driven by WAKIX sales, and reaffirms its 2025 revenue guidance.

Harmony Biosciences appoints Ron Philip, former CEO of Spark Therapeutics and current CEO of Orbital Therapeutics, to its Board of Directors, effective April 2, 2025.

Harmony Biosciences announces the appointment of Adam Zaeske as its new Chief Commercial Officer, effective March 31, 2025, succeeding Jeffrey Dierks who is stepping down for personal reasons.

Harmony Biosciences announces record Q4 and full-year 2024 financial results, driven by WAKIX sales, and reiterates its 2025 net revenue guidance.

Harmony Biosciences announced strong preliminary 2024 revenue and provided 2025 revenue guidance, along with updates on key clinical programs.

Certain shareholders of Harmony Biosciences Holdings, Inc. sold 8 million shares of common stock in a registered public offering, with an option for underwriters to purchase an additional 1.2 million shares.

Harmony Biosciences announced record net revenue of $186 million for Q3 2024, driven by strong sales of WAKIX and progress in its pipeline.

Harmony Biosciences presented a comprehensive pipeline update at its Investor Day, highlighting new data and strategic acquisitions aimed at driving significant revenue growth.

Harmony Biosciences announced a 29% year-over-year increase in net revenue for Q2 2024, driven by strong sales of WAKIX and progress in its pitolisant high-dose program.

Harmony Biosciences Holdings reports the immediate resignation of a board member due to health reasons and a name change for its subsidiary.

Harmony Biosciences held its 2024 Annual Meeting of Stockholders, electing three Class I directors and ratifying Deloitte & Touche LLP as its independent auditor for the fiscal year ending December 31, 2024.

Harmony Biosciences has promoted Kumar Budur to Executive Vice President and Chief Medical & Scientific Officer, effective May 1, 2024, with an increased base salary and equity grants.

Harmony Biosciences announced a 30% year-over-year net revenue growth for Q1 2024, driven by strong sales of WAKIX and strategic portfolio diversification.

Harmony Biosciences has secured an exclusive sublicense to develop and commercialize a novel orexin-2 receptor agonist for narcolepsy and other potential indications in the U.S. and Latin America.

Harmony Biosciences announced a 33% increase in full-year 2023 revenue, driven by strong sales of WAKIX, and provided updates on its clinical development programs.